2026年6月最新影响因子数据已更新，欢迎查询使用。如果您对期刊系统有任何需求或者问题，欢迎反馈给我们。
| 热门AI工具： |
论文引言生成
New
AI 写作痕迹检测
Hot
学术改写降重
论文讨论生成
参考文献挖掘工具
审稿意见辅助撰写
|
查看更多AI工具 >> |
| 近期推荐： | 热 全流程投稿协助套餐服务 | 热 SCI论文AI润色+人工QC服务 | 热 Springer Nature特刊征稿 |
 |
| 基本信息 | 登录收藏 | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名字 | LANCET ONCOLOGY LANCET ONCOL （此期刊被最新的JCR期刊SCIE收录） LetPub评分 9.8
51人评分
我要评分
声誉 10.0 影响力 9.7 速度 9.3 | |||||||||||||||||
| 期刊ISSN | 1470-2045 | 安装APP，查看期刊最新消息
| ||||||||||||||||
| E-ISSN | 1474-5488 | |||||||||||||||||
| 2025-2026最新IF （数据来源于网友提供） | 注册或登录后，查看IF | |||||||||||||||||
| 实时影响因子 | 截止2026年9月20日：21.21 | |||||||||||||||||
| 2025-2026自引率 | 1.8%点击查看自引率趋势图 | |||||||||||||||||
| 五年IF （数据来源于网友提供） | 40.503数据由网友[alphaoak803]收集提供 | |||||||||||||||||
| h-index | 274 | |||||||||||||||||
| CiteScore （ 2026年6月最新版） |
| |||||||||||||||||
| 期刊简介 |
| |||||||||||||||||
| 期刊官方网站 | http://www.thelancet.com/journals/lanonc/issue/current | |||||||||||||||||
期刊投稿格式模板 VIP专享 |
| |||||||||||||||||
| 期刊投稿网址 | https://www.editorialmanager.com/THELANCETONCOLOGY | |||||||||||||||||
| 该期刊中国学者近期发文 - New | SHR-A2102, a nectin-4 directed antibody-drug conjugate, in patients with pretreated advanced solid tumours: a multicentre, single-arm, phase 1 trial Author: Zhong, Runbo; Hong, Huangming; Yan, Min; Wang, Qiming; Zhang, Yan; Lan, Qiongyu; Luo, Yongzhong; Zhang, Ling; Xu, Haipeng; Guo, Sanxing; Guo, Wei; Ma, Jie; Zhang, Longzhen; Wu, Lin; Liu, Zhigang; He, Wei; Sun, Yubei; Chen, Kai; Huang, Jiangqiong; Han, Guang; Nian, Weiqi; Zhang, Ming; Ren, Shengxiang; Qiao, Rong; Li, Xiang; Yu, Meijing; Hu, Jin; Huang, Yanhua; Song, Li; Shi, Wei; Zhong, Hua Journal: LANCET ONCOLOGY. 2026; Vol. 27, Issue 9, pp. 1146-1157. DOI: 10.1016/S1470-2045(26)00238-X Ifebemtinib plus garsorasib in previously treated metastatic colorectal cancer with KRASG12C mutation: a multicentre, randomised, phase 1b/2 trial Author: Song, Zhengbo; Zhu, Liming; Liu, Ying; Lin, Rongbo; Li, Xingya; Luo, Yongzhong; Yuan, Yuan; Shi, Huaqiu; Zhang, Yiping; Zhang, Baoyuan; Zhu, Yinxin; Wang, Zaiqi; Cheng, Xiangdong Journal: LANCET ONCOLOGY. 2026; Vol. 27, Issue 9, pp. 1134-1145. DOI: 10.1016/S1470-2045(26)00175-0 Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial Author: Le, Xiuning; Passaro, Antonio; Zhao, Yuanyuan; Huang, Yan; Laskin, Janessa; Rodriguez-Abreu, Delvys; Calles, Antonio; Bazhenova, Lyudmila; Lo Russo, Giuseppe; Leighl, Natasha B.; Cappuzzo, Federico; Girard, Nicolas; Popat, Sanjay; Fang, Wenfeng; Luo, Yongzhong; Li, Wenting; He, Zhiyong; Zhao, Hui; Li, Mingjun; Song, Qibin; Zhao, Hongyun; El Darsa, Haidar; Monnet, Isabelle; Dols, Manuel Cobo; Campelo, Rosario Garcia; Jotte, Robert; Berz, David; Spira, Alexander; Perol, Maurice; Nagasaka, Misako; West, Howard; Styles, Lori; Li, Jianling; Clow, Fong; Goldman, Jonathan; Zhang, Li Journal: LANCET ONCOLOGY. 2026; Vol. 27, Issue 9, pp. 1094-1109. DOI: 10.1016/S1470-2045(26)00282-2 Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation-eligible hepatocellular carcinoma (EMERALD-3): a global, randomised, open-label, sponsor-blinded, phase 3 study Author: Kudo, Masatoshi; Abou-Alfa, Ghassan K.; Ren, Zhenggang; Heo, Jeong; Lencioni, Riccardo; Arai, Yasuaki; Bouattour, Mohamed; Gonzalez-Carmona, Maria A.; Guo, Yabing; Xu, Ai-Bing; Alves, Gustavo Vasconcelos; Dechaphunkul, Arunee; Ho, Gwo Fuang; Ni Lim, Yueh; Hu, HongTao; Liu, Ruibao; Gu, Shanzhi; Ostwal, Vikas; Manasirisuk, Witsarut; Chiu, Chang-Fang; Tekumalla, Sri Harsha; Shroff, Manish; Dave, Vimal; Rahma, Osama; Erinjeri, Joseph P.; Fan, Jia Journal: LANCET ONCOLOGY. 2026; Vol. 27, Issue 9, pp. 1077-1093. DOI: 10.1016/S1470-2045(26)00278-0 | |||||||||||||||||
| 期刊语言要求 | 经LetPub语言功底雄厚的美籍native English speaker精心编辑的稿件，不仅能满足LANCET ONCOLOGY的语言要求，还能让LANCET ONCOLOGY编辑和审稿人得到更好的审稿体验，让稿件最大限度地被LANCET ONCOLOGY编辑和审稿人充分理解和公正评估。LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）帮助作者准备稿件，已助力全球15万+作者顺利发表论文。部分发表范例可查看：服务好评 论文致谢 。
提交文稿 | |||||||||||||||||
| 是否OA开放访问 | No | |||||||||||||||||
| 通讯方式 | ELSEVIER SCIENCE INC, 360 PARK AVE SOUTH, NEW YORK, USA, NY, 10010-1710 | |||||||||||||||||
| 出版商 | Lancet Publishing Group | |||||||||||||||||
| 涉及的研究方向 | 医学-肿瘤学 | |||||||||||||||||
| 出版国家或地区 | UNITED STATES | |||||||||||||||||
| 出版语言 | English | |||||||||||||||||
| 出版周期 | Monthly | |||||||||||||||||
| 出版年份 | 2000 | |||||||||||||||||
| 年文章数 | 174点击查看年文章数趋势图 | |||||||||||||||||
| Gold OA文章占比 | 16.45% | |||||||||||||||||
| 研究类文章占比： 文章 ÷（文章 + 综述） | 79.89% | |||||||||||||||||
| WOS期刊JCR分区 （ 2025-2026年最新版） | 注册或登录后，查看WOS分区等级 | |||||||||||||||||
| 期刊分区表预警名单 | 2026年03月发布的新锐学术版：不在预警名单中 2025年03月发布的2025版：不在预警名单中 2024年02月发布的2024版：不在预警名单中 2023年01月发布的2023版：不在预警名单中 2021年12月发布的2021版：不在预警名单中 2020年12月发布的2020版：不在预警名单中 | |||||||||||||||||
  | ||||||||||||||||||
| 《新锐期刊分区表》 （ 2026年3月发布） | 点击查看期刊分区表趋势图
| |||||||||||||||||
| 期刊分区表 （ 2025年3月升级版） |
| |||||||||||||||||
| 期刊分区表 （ 2023年12月旧的升级版） |
| |||||||||||||||||
| SCI期刊收录coverage | Science Citation Index Expanded (SCIE) (2020年1月，原SCI撤销合并入SCIE，统称SCIE) Scopus (CiteScore) | |||||||||||||||||
| PubMed Central (PMC)链接 | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=1470-2045%5BISSN%5D | |||||||||||||||||
| 平均审稿速度 | 网友分享经验： 一般,3-8周 | |||||||||||||||||
| 平均录用比例 | 网友分享经验： 极难 | |||||||||||||||||
| LetPub助力发表 | 经LetPub编辑的稿件平均录用比例是未经润色的稿件的1.5倍，平均审稿时间缩短40%。众多作者在使用LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）后论文在LANCET ONCOLOGY顺利发表。
快看看作者怎么说吧：服务好评 论文致谢 。 提交文稿 | |||||||||||||||||
| 期刊常用信息链接 |
| |||||||||||||||||
|
|
| |
| 中国学者近期发表的论文 | |
| 1. | SHR-A2102, a nectin-4 directed antibody-drug conjugate, in patients with pretreated advanced solid tumours: a multicentre, single-arm, phase 1 trial Author: Zhong, Runbo; Hong, Huangming; Yan, Min; Wang, Qiming; Zhang, Yan; Lan, Qiongyu; Luo, Yongzhong; Zhang, Ling; Xu, Haipeng; Guo, Sanxing; Guo, Wei; Ma, Jie; Zhang, Longzhen; Wu, Lin; Liu, Zhigang; He, Wei; Sun, Yubei; Chen, Kai; Huang, Jiangqiong; Han, Guang; Nian, Weiqi; Zhang, Ming; Ren, Shengxiang; Qiao, Rong; Li, Xiang; Yu, Meijing; Hu, Jin; Huang, Yanhua; Song, Li; Shi, Wei; Zhong, Hua Journal: LANCET ONCOLOGY. 2026; Vol. 27, Issue 9, pp. 1146-1157. DOI: 10.1016/S1470-2045(26)00238-X PubMed DOI |
| 2. | Ifebemtinib plus garsorasib in previously treated metastatic colorectal cancer with KRASG12C mutation: a multicentre, randomised, phase 1b/2 trial Author: Song, Zhengbo; Zhu, Liming; Liu, Ying; Lin, Rongbo; Li, Xingya; Luo, Yongzhong; Yuan, Yuan; Shi, Huaqiu; Zhang, Yiping; Zhang, Baoyuan; Zhu, Yinxin; Wang, Zaiqi; Cheng, Xiangdong Journal: LANCET ONCOLOGY. 2026; Vol. 27, Issue 9, pp. 1134-1145. DOI: 10.1016/S1470-2045(26)00175-0 PubMed DOI |
| 3. | Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial Author: Le, Xiuning; Passaro, Antonio; Zhao, Yuanyuan; Huang, Yan; Laskin, Janessa; Rodriguez-Abreu, Delvys; Calles, Antonio; Bazhenova, Lyudmila; Lo Russo, Giuseppe; Leighl, Natasha B.; Cappuzzo, Federico; Girard, Nicolas; Popat, Sanjay; Fang, Wenfeng; Luo, Yongzhong; Li, Wenting; He, Zhiyong; Zhao, Hui; Li, Mingjun; Song, Qibin; Zhao, Hongyun; El Darsa, Haidar; Monnet, Isabelle; Dols, Manuel Cobo; Campelo, Rosario Garcia; Jotte, Robert; Berz, David; Spira, Alexander; Perol, Maurice; Nagasaka, Misako; West, Howard; Styles, Lori; Li, Jianling; Clow, Fong; Goldman, Jonathan; Zhang, Li Journal: LANCET ONCOLOGY. 2026; Vol. 27, Issue 9, pp. 1094-1109. DOI: 10.1016/S1470-2045(26)00282-2 PubMed DOI |
| 4. | Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation-eligible hepatocellular carcinoma (EMERALD-3): a global, randomised, open-label, sponsor-blinded, phase 3 study Author: Kudo, Masatoshi; Abou-Alfa, Ghassan K.; Ren, Zhenggang; Heo, Jeong; Lencioni, Riccardo; Arai, Yasuaki; Bouattour, Mohamed; Gonzalez-Carmona, Maria A.; Guo, Yabing; Xu, Ai-Bing; Alves, Gustavo Vasconcelos; Dechaphunkul, Arunee; Ho, Gwo Fuang; Ni Lim, Yueh; Hu, HongTao; Liu, Ruibao; Gu, Shanzhi; Ostwal, Vikas; Manasirisuk, Witsarut; Chiu, Chang-Fang; Tekumalla, Sri Harsha; Shroff, Manish; Dave, Vimal; Rahma, Osama; Erinjeri, Joseph P.; Fan, Jia Journal: LANCET ONCOLOGY. 2026; Vol. 27, Issue 9, pp. 1077-1093. DOI: 10.1016/S1470-2045(26)00278-0 PubMed DOI |
| 5. | Local management of second ipsilateral breast cancer events after primary breast-conserving therapy: an international consensus Author: Hannoun-Levi, Jean-Michel; Margenthaler, Julie A.; Anderson, Bethany; Di Micco, Rosa; Arthur, Douglas W.; Aznar, Marianne; Burke, Erin E.; de Boniface, Jana; Dietz, Jill R.; Dodwell, David; Fredriksson, Irma; Gentilini, Oreste D.; Guix, Benjamin; Gutierrez, Cristina; Kothari, Ashutosh; Lyons, Janice A.; Meattini, Icro; Montero-Luis, Angel; Mourtada, Firas; Nguyen, Toan T.; Polgar, Csaba; Poortmans, Philip; Rocco, Nicola; Sackey, Helena; Sarantou, Terry; Showalter, Shayna L.; Strnad, Vratislav; Kuehn, Thorsten; Volders, Jose; Vrancken-Peeters, Marie-Jeanne; Yashar, Catheryn; Rubio, Isabel T.; Gahm, Jessica; Zeidan, Youssef; Kaidar-Person, Orit; Dirbas, Frederick M Journal: LANCET ONCOLOGY. 2026; Vol. 27, Issue 9, pp. e407-e419. DOI: 10.1016/S1470-2045(26)00177-4 PubMed DOI |
| 6. | Adjuvant alectinib versus chemotherapy in resected ALK- positive non-small-cell lung cancer (ALINA): health-related quality-of-life and safety outcomes from a randomised, open-label, phase 3 trial Author: Dziadziuszko, Rafal; Ahn, Jin Seok; Barlesi, Fabrice; Solomon, Benjamin J.; Wu, Yi-Long; Bondarenko, Igor; Hochmair, Maximilian; Horinouchi, Hidehito; Lee, Dae Ho; Lee, Jong-Seok; Planchard, David; Rittmeyer, Achim; Zhong, Wenzhao; Adler, Leah; Archer, Venice; Cardona, Andres; Petric, Patricia; Scalori, Astrid; Ding, Beiying; Mamolo, Carla; Smoljanovic, Vlatka; Nishio, Makoto Journal: LANCET ONCOLOGY. 2026; Vol. 27, Issue 9, pp. 1110-1119. DOI: 10.1016/S1470-2045(26)00283-4 PubMed DOI |
| 7. | Efficacy and safety of dabrafenib plus trametinib in adults with differentiated thyroid cancer: a randomised, doubleblind, placebo-controlled, phase 3 trial Author: Gao, Ming; Park, Young Joo; Lin, Chia-Chi; Krzyzanowska, Monika K.; Li, Zhiyong; Tsai, Hui-Jen; Shi, Feng; Qin, Jianwu; Choong, Swee Hsia; Lin, Yansong; Zhang, Yuan; Kang, Jin H.; Hoff, Ana O.; Tan, Monique; Roughton, Michael; Paul, Michaela; Wirth, Lori J Journal: LANCET ONCOLOGY. 2026; Vol. 27, Issue 8, pp. 994-1003. DOI: 10.1016/S1470-2045(26)00133-6 PubMed DOI |
| 8. | Trastuzumab rezetecan versus pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer (HORIZON-Breast01): interim analysis of a multicentre, open-label, randomised, controlled, phase 3 trial Author: Yao, Herui; Zhang, Qingyuan; Li, Huiping; Yin, Yongmei; Wang, Shusen; Ouyang, Quchang; Sun, Tao; Li, Wei; Wang, Xiaojia; Yan, Min; Wang, Biyun; Cheng, Jing; Tong, Zhongsheng; Wei, Wei; Wang, Xinshuai; Xie, Weimin; Sun, Zhengkui; Yuan, Peng; Geng, Cuizhi; Gan, Lu; Han, Xinghua; Li, Wenfeng; Zhou, Shoubing; Yan, Xi; Gao, Jinnan; Yi, Tienan; Wu, Jingna; Niu, Zhaofeng; Fu, Fangmeng; Nie, Jianyun; Wang, Yongsheng; Zhao, Bing; Wu, Zhiyong; Zhu, Zhengqiu; Yang, Yaping; Zhao, Jianli; Sheng, Zhen; Zhang, Ying; Cheng, Lin; Zhu, Xiaoyu; Song, Erwei Journal: LANCET ONCOLOGY. 2026; Vol. 27, Issue 8, pp. 929-940. DOI: 10.1016/S1470-2045(26)00193-2 PubMed DOI |
| 9. | Neoadjuvant toripalimab plus celecoxib versus toripalimab monotherapy for mismatch repair-deficient or microsatellite instability-high, locally advanced colorectal cancer (PICC-2) an open-label, multicentre, randomised, phase 2trial Author: Hu, Huabin; Shen, Xutao; Li, Yunfeng; Zhou, Jiaming; Liu, Ping; Zhang, Jianwei; Hou, Yujie; Wang, Xiaozhong; Deng, Jiaye; Zheng, Zhuoxin; Li, Jianxia; Lan, Ping; Wu, Xiaojian; Kang, Liang; Huang, Meijin; He, Zhen; He, Xiaosheng; Yang, Zuli; Huang, Liang; Wang, Hui; Wang, Huaiming; Luo, Shuangling; Chen, Dianke; Xie, Xiaoyu; Zhang, Yan; Zhai, Xiaohui; Li, Shanshan; Li, Weiwei; Hu, Jiancong; Yang, Tao; Wang, Chao; Deng, Weihao; Huang, Yan; Cao, Wuteng; Li, Fangqian; Shi, Lishuo; Ling, Li; Deng, Yanhong Journal: LANCET ONCOLOGY. 2026; Vol. 27, Issue 8, pp. 1020-1030. DOI: 10.1016/S1470-2045(26)00220-2 PubMed DOI |
| 10. | Treatment-related adverse events of CD3-based T cell-engaging bispecific antibodies in patients with cancer: a meta-analysis of clinical trials Author: Zhu, Youwen; Liu, Kun; Rosen, Steven T.; Liu, Wei; Zhu, Hong Journal: LANCET ONCOLOGY. 2026; Vol. 27, Issue 7, pp. 893-902. DOI: 10.1016/S1470-2045(26)00086-0 PubMed DOI |
|
|
  | ||||||||||||||||
|
投稿状态统计： 我要评分： | ||||||||||||||||
| 投稿前担心稿件结构或语言不够规范？试试稿件自查工具，一键检测 >> | ||||||||||||||||
|
||||||||||||||||
同领域作者分享投稿经验：共42条 |
||||||||||||||||
|
|
联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们
© 2010-2026 中国: LetPub上海 网站备案号：沪ICP备10217908号-1 
沪公网安备号：31010402006960 （网站）31010405000484 （蝌蝌APP）
增值电信业务经营许可证：沪B2-20211595 网络文化经营许可证：沪网文[2023]2004-152号
礼翰商务信息咨询（上海）有限公司 办公地址：上海市徐汇区漕溪北路88号圣爱大厦1803室
安全保密
投稿信 (Cover Letter) 模板
